#USA #New York #Class Action #Levi & Korsinsky #Capricor Therapeutics

Important Update for Capricor Shareholders

Levi & Korsinsky, LLP has issued a reminder to investors regarding an important deadline related to a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who suffered losses during the period of alleged securities fraud are urged to take action before September 15, 2025. This class action aims to recover losses incurred by investors due to misleading statements made by the company.

Background of the Case

The lawsuit in question addresses claims of securities fraud that occurred between October 9, 2024, and July 10, 2025. It's alleged that during this period, Capricor provided investors with optimistic information regarding its leading cell therapy candidate, deramiocel, especially in relation to its potential FDA approval for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

Regrettably, these statements were accompanied by false assertions and significant omissions concerning the drug's safety and efficacy data. On July 11, 2025, Capricor issued a press release revealing that the FDA had denied the Biologics License Application (BLA), stating that the application did not meet the necessary requirements for substantial evidence of effectiveness and highlighted the need for further clinical data. The press release led to a considerable stock price drop, plummeting from $11.40 per share to $7.64 in just one day, showcasing the financial impact of these statements on shareholders.

Your Rights as a Shareholder

For those who held shares of Capricor during this critical timeframe, it's essential to know your rights. Investors have until September 15, 2025, to request the court to appoint them as lead plaintiff in this case. Importantly, participation in any potential recovery does not necessitate that you serve in the lead plaintiff role. If you're a class member, you may be eligible for compensation without any upfront costs or fees.

Why Choose Levi & Korsinsky?

For over 20 years, Levi & Korsinsky has been at the forefront of defending shareholders' rights, securing hundreds of millions for aggrieved investors through successful litigation. The firm has achieved recognition, ranking consistently among the top securities litigation firms in the United States, as per the ISS Securities Class Action Services rankings. With a dedicated team of over 70 professionals, Levi & Korsinsky is equipped to provide expert support in complex securities cases.

How to Get Involved

If you are a Capricor investor impacted by the alleged securities fraud, now is the time to act. You can reach out for more information or to express your interest in participating in the lawsuit through their official channels.

For inquiries, please contact:

• - Joseph E. Levi, Esq.
• - Email: [email protected]
• - Phone: (212) 363-7500

Do not miss this opportunity to seek compensation for the losses you may have incurred as a shareholder in Capricor Therapeutics. The deadline is approaching fast, and swift action is required to protect your rights.